Publications
167
Citations
2,539
Est. group size
~38
Recurring co-author estimate
Active years
43
Publishing since 1984
David A. Bond conducts clinical research on blood cancers, particularly lymphomas (such as diffuse large B-cell lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and Burkitt lymphoma) and chronic lymphocytic leukemia. His work focuses on treatment outcomes, prognostic factors, and emerging therapies including CAR-T cell therapy, BTK inhibitors, and other targeted drugs, often drawing on large multicenter and real-world patient datasets.
Publication output has grown substantially over the past decade, rising from a handful of papers in 2017-2018 to a sustained rate of roughly 20-26 per year since 2021.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 419 | MULTICENTER REAL‐WORLD OUTCOMES IN DIFFUSE LARGE B‐CELL LYMPHOMA PROFILED WITH A COMMERCIALLY‐AVAILABLE CIRCULATING TUMOR DNA ASSAY
Hematological Oncology · 2025
- ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C
Blood · 2025
- Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma
Blood · 2025
- High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Blood Advances · 2024
- A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma
Blood · 2024
- Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.
Journal of Clinical Oncology · 2024
- High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Blood Advances · 2023
- Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 <scp>U.S.</scp> cancer centers
American Journal of Hematology · 2023
- Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
Blood Advances · 2023
- EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort
Leukemia & lymphoma/Leukemia and lymphoma · 2023
- TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma
Haematologica · 2023
- NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
Blood · 2022
- CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies
Frontiers in Immunology · 2022
- High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
Blood · 2022
- P007 Novel integration of a digital patient-reported outcome measure into an NHS electronic health record
Lara D. Veeken · 2022
- Blood×65
- Blood Advances×17
- Hematological Oncology×11
- Journal of Clinical Oncology×10
- Clinical Lymphoma Myeloma & Leukemia×6
- Beth Christian
Medicine · The Ohio State University
- Kaitlin Annunzio
Medicine · The Ohio State University
- Timothy Voorhees
Medicine · The Ohio State University
- Narendranath Epperla
Medicine · The Ohio State University
- Kami J. Maddocks
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile